Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ups And Downs See Mid-Table Players Shift Position

Leading Industry Players Jostle In The Middle Of Our Top 50 Ranking

Executive Summary

Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.

You may also be interested in...



Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Amneal Aims To Bolster Generics Margins

Amneal says it is taking initiatives to improve its generics margins by improving its manufacturing and supply chain, after its generics segment was sales drop by 11% in the first quarter. Amneal is aiming to deliver six to seven high-value products annually, while the company is also looking to launch three biosimilars in the next couple of years.

Celltrion Sees Double-Digit Growth In Sales And Profit

South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel